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Aim: Treatment of chronic myeloid leukemia patients with the second and
third generation BCR-ABL1 tyrosine kinase inhibitors (TKIs) increases
cardiovascular side effects including myocardial infarction. We investi-
gated the effect of these TKIs on cardiovascular risk factors (plasma lipids,
blood pressure, inflammation markers, endothelial dysfunction) and
development of atherosclerosis, in a translational model for atheroscle-
rosis, the APOE3*Leiden.CETP mouse.
Methods: First, dose and dosage interval were determined by PK analysis
to reach similar plasma concentrations as in patients. Next, mice were
treated for sixteenweeks with imatinib (150 mg/kg BID), nilotinib (30 mg/
kg QD) or ponatinib (10 mg/kg QD), as representatives of the first, second
and third generation TKIs. Cardiovascular risk factors were analyzed
throughout, and histopathological analysis of atherosclerosis and gene
expression and pathway analysis in the liver as predictor tissue were
performed.
Results: Imatinib and ponatinib decreased plasma cholesterol (-69%,
P<0.001 and -37%, P<0.001) and atherosclerotic lesion area (-78%,
P<0.001 and -48% P¼0.001), which were not affected by nilotinib. In
addition, imatinib reduced inflammation markers and increased plaque
stability. Ponatinib increased E-selectin levels (161%, P<0.05) and the
urinary albumin:creatinin ratio (13-fold, N.S.). All three TKIs decreased
pro-inflammatory Ly6Chigh monocytes, consistent with the mode of
action of TKIs. Gene expression pathway analysis confirmed our findings
on decreased cardiovascular risk by imatinib and increased risk by
ponatinib.
Conclusions: Imatinib showed a beneficial cardiovascular risk profile and
nilotinib had no adverse cardiovascular effects, whereas ponatinib despite
favorable effects on plasma lipids and atherosclerosis increased the car-
diovascular risk through increased inflammation and endothelial activa-
tion.SAG004.
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Aim: Aspirin (ASA) is the first-line therapy for the secondary prevention of
cardiovascular events(1). Platelet response to ASA is highly variable be-
tween individuals, and is associated with varying risks of bleeding. This
study aimed to examine the role of platelet surface receptors and blood
group in determining this risk of bleeding attributable to ASA.
Methods: Platelet GPIb-IX-V receptor binds VWF and initiates platelet
aggregation by capturing platelets to damaged subendothelium. GPIIb/IIIa
receptor binds fibrinogen and is essential in the formation of a primary
platelet plug by mediating cross-linkage of platelets. We recruited 20
healthy volunteers and administered 300mg ASA. We evaluated the
standard response of ASA to Arachidonic Acid- induced platelet aggrega-
tion using Light Transmission Aggregometry. Plasma TxB2 (product of
activated platelets) and Glycocalicin (soluble GPIb normally found in
plasma) were measured using ELISA. The surface expression of GPIIB/IIIa
and GPIb were measured using flow cytometry.
Results: LTA and post-ASA TxB2 demonstrated standard effects of ASA
on platelet aggregation (p<0.0001, student t-test, n¼19 and p<0.0001,
student t-test, n¼20 respectively). Donors with blood group O had
significantly less surface expression of GPIb counts compared to non-O
donors (p¼0.0288, student t-test, n¼10). Interestingly, both groups had
almost identical Glycocalicin post- ASA, suggesting that the reduced
GPIb expression in blood group O can’t be explained by shed plasma
GPIb.Conclusions: Our results suggest for the first time that blood group plays a
crucial role in platelet GPIb-IX-V receptor expression, independent of
plasma Glycocalicin levels. This can be used to possibly determine the
individual risk of ASA bleeding.SAG005.
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Aim: Graft patency is one of the major determinant of long-term outcome
following coronary artery bypass grafting (CABG). The identification of
predictors of graft patency after CABG has been addressed by several
studies but none has assessed the potential involvement of microvesicles
(MVs). MVs are biomarkers of vascular injury and inflammation in several
cardiovascular diseases including atherothrombosis. The aim of the study
was to elucidate whether a specific “signature” of MVs is associated with
CABG occlusion.
Methods: MVs were analyzed in platelet free plasma (PFP) collected from
179 patients the day before elective surgical myocardial revascularization
(T0). At 18 month-follow-up, a 64-rows CT scan evaluation of graft patency
was performed. The number of MVs, their cell origin and the expression of
platelet activation markers (P-selectin, CD40L, TF) were evaluated by flow
cytometry.
Results: Analysis of MV signature at T0 indicated that patients that would
have occluded bypass at follow-up had higher number of CD41pos, Psel/
CD41pos and CD40L/CD41pos MVs. No significant differences were
observed when monocyte-, granulocyte- and endothelium-derived MVs
were analyzed. Of interest, TF/CD41pos MVs were increased in occluded
compared to patent graft patients (64±40 vs 17±7 MVs/ml, p¼0.0002). ROC
curve analysis confirmed the predictive value of TF/CD41pos MV-signature
in the assessment of CABG occlusion (AUC: 0.81; p<0.0001).
Conclusions: These data show that patients that would have occluded
bypass-graft had a significant higher number of MVs compared to patients
with patent graft. Moreover these data provide the evidence that the
signature of MVs before CABG surgery has a predictive value of graft
patency.SAG006.
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Aim: Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) plays a major role
in the regulation of LDL-receptor function and therapy with PCSK9 in-
hibitors have shown efficacy in reducing LDL-cholesterol levels whereas
their effects on platelets are unknown.
Aim of the study was to evaluate, in adults with hypercholesterolemia, the
effects of therapy with monoclonal antibody anti-PCSK9 on platelet
function.
Methods: 21 subjects with hypercholesterolemia (14M/7F, age 56.2±11.5
years, BMI 25.5±4.5 kg/m2) were enrolled and most of them (n¼14) were
on acetylsalicylic acid (ASA). At baseline and after a 8-week treatment with
the PCSK9 inhibitors Alirocumab or Evolocumab, we evaluated lipid profile
and the folllowing platelet parameters: i)aggregation in platelet-rich
plasma(PRP) and whole blood(WB) to agonists, ii)adhesion and
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expression of the activation marker CD62P (cytofluorimetric assay).
Results: A 8-week treatment with anti-PCSK9 therapy reduced total-
cholesterol by 41±5% (p<0.001), LDL-cholesterol by 55±4% (p<0.001), and
triglycerides by 15±2% (p<0.01). In ASA-treated subjects, we found: a
decrease of platelet aggregation in PRP to ADP (-33±2%, p<0.01), and
collagen (-27±5%, p<0.001); an increase of closure time of PFA-100
(+70±7%, p<0.02); a decrease of CD62P expression (-49±8%, p<0.03); in
non-ASA treated subjects: a decrease of aggregation in PRP to ADP
(-24±6%, p<0.05), and collagen (-31±4%, p<0.05); a decrease of aggrega-
tion in WB to ADP (-51±9%,p<0.04), and collagen (-44±2%,p<0.02); a
decrease of CD62P expression (-47±3%,p<0.003).
Conclusions: In adults with hypercholesterolemia, a 8-week treatment
with monoclonal antibody anti-PCSK9 significantly improved lipid profil,
reduced platelet reactivity to agonists and increased platelet sensitivity to
the inhibitory effects of aspirin.SAG007.
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Aim: Anti-platelet therapy with aspirin (ASA) reduces nonfatal myocardial
infarction, stroke, and cardiovascular death by irreversibly inhibiting
platelet COX-1 and TxA2 production. However, variable TxA2 inhibition is
common. We studied the relationship of urinary 11dhTxB2, an inactive
TxA2 metabolite, with all-cause mortality in stable coronary artery disease
(CAD) patients on ASA treatment.
Methods: CAD patients (n¼449) taking ASA from Baylor Heart and
Vascular Hospital and Texas Heart Hospital Baylor Plano were studied.
Results: There were 73% males and 27% females with a mean age of
66.5±10 and 65±10.2, respectively. A positive linear trend for age
(p¼0.01), chronic obstructive pulmonary disease (p¼0.0003), heart
failure (p¼0.003), and oxidative stress (p<0.001) was observed among
11dhTxB2 tertiles. There were more females (p¼0.001) in the upper
tertiles. There was no difference in ASA dosage and P2Y12 antagonist
use (p¼0.53) between 11dhTxB2 tertiles (p¼0.22). 14.9% patients died
over a median follow-up of 3 years with 87.5% deaths from cardiovas-
cular causes. 38.8% non-survivors received P2Y12 antagonists compared
to 42.2% survivors (p¼0.61). The mortality rate in the upper tertile was
8.1 compared to 5.1 and 0.7 in middle and lower tertiles (p<0.001). By
stepwise Cox hazard analysis, patients in the middle (HR¼7.14; 95%
CI:2.46-20.68) and upper 11dhTxB2 tertiles (HR¼9.91; 95%CI:3.45-
28.50) had a higher risk for mortality after adjusting for age and co-
morbidities.
Conclusions: Urinary 11dhTxB2 is a strong independent risk factor for all-
cause mortality among stable CAD patients on ASA therapy. These results
suggest that inadequate response to ASA may prompt additional anti-
platelet therapy in these high risk patients.SAG008.
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Aim: To assess the possibility of using the novel strain rate imaging
method in the detection of significant regional myocardial ischemia
caused by significant coronary artery disease in patients with stable cor-
onary artery disease.
Methods: Thirty patients with SCAD and significant single vessel left
anterior descending (LAD) coronary artery stenosis, diagnosed by invasive
coronary angiography, undergoing elective percutaneous coronary inter-
vention (PCI) of the LAD lesion with no significant lesions in the other
coronary vessels, left circumflex (LCX) and right coronary artery (RCA).
Patients with diabetes, regional wall motion and reduced left ventricular
systolic function were excluded.
Regional systolic strain and strain rate was measured in the ischemic LAD
segments which are six, apicoseptal, mid anteroseptal, basal anteroseptal,
apicoanterior, mid anterior and basal anterior, and measured in the non-
ischemic LCX and RCA segments, before elective PCI of LAD and three
months later.
Results: By comparing the strain and strain rate of the ischemic segments
before and after PCI there was significant improvement of the systolic
strain while there were non-significant changes in the non-ischemic seg-
ments.Conclusions: Tissue Doppler strain and strain rate imaging during resting
echocardiography can be used to detect regional myocardial ischemia in
patients with significant coronary artery stenosis.
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Aim: Neuronal guidance cues (NGCs) are known for controlling neuronal
migration and vascular patterning through a complex interplay of signals.
It has been shown that NGCs and their receptors play an important role in
the regulation of the adhesion of monocytes to the vascular endothelium
and their subsequent proatherogenic actions. However, the role of NGCs in
human atherosclerosis is not well studied.Because we know that mono-
cyte adhesion and the vascular endothelium permeability play an impor-
tant role in the atherosclerotic process, we hypothesize that a
dysfunctional NGC pathway contribute to this in patients with premature
atherosclerosis (PAS) and no cardiovascular risk factors.
